College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China.
Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China.
Front Immunol. 2022 Jul 19;13:939940. doi: 10.3389/fimmu.2022.939940. eCollection 2022.
T cell receptor-engineered T cells (TCR-Ts) have emerged as potent cancer immunotherapies. While most research focused on classical cytotoxic CD8 T cells, the application of CD4 T cells in adoptive T cell therapy has gained much interest recently. However, the cytotoxic mechanisms of CD4 TCR-Ts have not been fully revealed. In this study, we obtained an MHC class I-restricted MART-1-specific TCR sequence based on the single-cell V(D)J sequencing technology, and constructed MART-1-specific CD4 TCR-Ts and CD8 TCR-Ts. The antitumor effects of CD4 TCR-Ts were comparable to those of CD8 TCR-Ts and . To delineate the killing mechanisms of cytotoxic CD4 TCR-Ts, we performed single-cell RNA sequencing and found that classical granule-dependent and independent cytolytic pathways were commonly used in CD4 and CD8 TCR-Ts, while high expression of and various costimulatory receptors were unique features for cytotoxic CD4 TCR-Ts. Further signaling pathway analysis revealed that transcription factors Runx3 and Blimp1/Tbx21 were crucial for the development and killing function of cytotoxic CD4 T cells. Taken together, we report the antitumor effects and multifaceted killing mechanisms of CD4 TCR-Ts, and also indicate that MHC class I-restricted CD4 TCR-Ts could serve as potential adoptive T cell therapies.
T 细胞受体工程化 T 细胞(TCR-Ts)已成为强大的癌症免疫疗法。虽然大多数研究都集中在经典的细胞毒性 CD8 T 细胞上,但最近 CD4 T 细胞在过继性 T 细胞治疗中的应用引起了广泛关注。然而,CD4 TCR-Ts 的细胞毒性机制尚未完全揭示。在这项研究中,我们基于单细胞 V(D)J 测序技术获得了一种 MHC Ⅰ类限制的 MART-1 特异性 TCR 序列,并构建了 MART-1 特异性 CD4 TCR-Ts 和 CD8 TCR-Ts。CD4 TCR-Ts 的抗肿瘤效果与 CD8 TCR-Ts 相当。为了阐明细胞毒性 CD4 TCR-Ts 的杀伤机制,我们进行了单细胞 RNA 测序,发现经典的颗粒依赖性和非依赖性细胞溶解途径在 CD4 和 CD8 TCR-Ts 中都被共同使用,而高表达和各种共刺激受体是细胞毒性 CD4 TCR-Ts 的独特特征。进一步的信号通路分析表明,转录因子 Runx3 和 Blimp1/Tbx21 对于细胞毒性 CD4 T 细胞的发育和杀伤功能至关重要。综上所述,我们报告了 CD4 TCR-Ts 的抗肿瘤作用和多方面的杀伤机制,并表明 MHC Ⅰ类限制的 CD4 TCR-Ts 可以作为潜在的过继性 T 细胞治疗方法。